2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Myelodysplastic Syndromes
5
Neoplasms
4
Leukemia, Myeloid, Acute
4
Leukemia, Myelomonocytic, Chronic
3
Carcinoma, Squamous Cell
3
Primary Myelofibrosis
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia
2
Head and Neck Neoplasms
2
Cytopenia
2
Anemia, Refractory, with Excess of Blasts
2
Waldenstrom Macroglobulinemia
1
Thrombocythemia, Essential
1
Squamous Cell Carcinoma of Head and Neck
1
Splenomegaly
1
Solid Tumor
1
Polycythemia Vera
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Melanoma
1
Malignant Neoplasmas
1
Lymphoma, Mantle-Cell
1
Leukemia, Hairy Cell
1
Esophageal Squamous Cell Carcinoma
1
Epidermolysis Bullosa Dystrophica
1
Interventions
ON 01910
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Epidermolysis Bullosa Dystrophica
×
ON 01910
×
Clear all
NCT03786237
2026-02-24
Rigosertib for RDEB-SCC
Salzburger Landeskliniken
Phase 1/2
Completed
2 enrolled